News Search Results
Oct 01, 2025, 09:21 ET Kazia Therapeutics Supports Australian MRFF-Funded Project Developing AI-Driven Sequential Therapy Strategy for DIPG/DMG
standard approval. Other clinical trials involving paxalisib are ongoing in advanced breast cancer, brain metastases, diffuse midline gliomas, and primary CNS lymphoma, with several of these trials having reported encouraging interim data. Paxalisib was granted Orphan Drug Designation for glioblastoma by the
More news about: Kazia Therapeutics Limited
Oct 01, 2025, 08:53 ET Mercury Bio Reports Positive Results from Preclinical Study Evaluating Novel Drug Delivery Technology Transporting Protein Cargo to the Brain
brain cells." The blood-brain barrier (BBB) forms a protective shield around the brain, insulating the central nervous system (CNS) from pathogens, toxins, hormones, and other substances in the blood that could disrupt brain function. This role is essential for survival but makes
More news about: Mercury Bio Inc.
Oct 01, 2025, 00:58 ET LG CNS Leverages Manufacturing AX Tech to Target the Middle East Oil Market
Oct. 1, 2025 /PRNewswire/ -- LG CNS, a leading AX (AI Transformation) company in Korea, is set to expand into Middle Eastern markets with its advanced manufacturing-focused AX technologies. From September 30 to October 2, LG CNS participated in the International Downstream
More news about: LG CNS
Sep 30, 2025, 07:00 ET NLS Pharmaceutics Shareholders Approve Merger with Kadimastem and Related Proposals at Extraordinary General Meeting
Pharmaceutics Ltd. (NASDAQ: NLSP) (NASDAQ: NLSPW) ("NLS"), a Swiss clinical-stage biopharmaceutical company focused on central nervous system ("CNS") disorders, and Kadimastem Ltd. (TASE: KDST) ("Kadimastem"), an advanced clinical-stage
More news about: NLS Pharmaceutics Ltd.; Kadimastem Ltd.
Sep 29, 2025, 17:52 ET Cohen & Steers Closed-End Opportunity Fund, Inc. (FOF) Notification of Sources of Distribution Under Section 19(a)
https://www.cohenandsteers.comSymbol: (NYSE: CNS)
More news about: Cohen & Steers, Inc.
Sep 29, 2025, 17:51 ET Cohen & Steers Total Return Realty Fund, Inc. (RFI) Notification of Sources of Distribution Under Section 19(a)
https://www.cohenandsteers.comSymbol: (NYSE: CNS)
More news about: Cohen & Steers, Inc.
Sep 29, 2025, 17:39 ET Cohen & Steers REIT and Preferred and Income Fund, Inc. (RNP) Notification of Sources of Distribution Under Section 19(a)
https://www.cohenandsteers.com/Symbol: (NYSE: CNS)
More news about: Cohen & Steers, Inc.
Sep 29, 2025, 17:35 ET Cohen & Steers Quality Income Realty Fund, Inc. (RQI) Notification of Sources of Distribution Under Section 19(a)
https://www.cohenandsteers.comSymbol: (NYSE: CNS)
More news about: Cohen & Steers, Inc.
Sep 29, 2025, 17:28 ET Cohen & Steers Infrastructure Fund, Inc. (UTF) Notification of Sources of Distribution Under Section 19(a)
https://www.cohenandsteers.comSymbol: (NYSE: CNS)
More news about: Cohen & Steers, Inc.
Sep 29, 2025, 10:00 ET iQure Pharma Secures US Patent for iQ-007, a First-in-Class Small Molecule Restoring Glutamate Balance in CNS Disorders
2025 /PRNewswire/ -- iQure Pharma, a clinical-stage biotech company breaking the cycle of excitotoxicity by restoring glutamate balance to treat CNS disorders, today announced that the United States Patent and Trademark Office (USPTO) has granted a US patent for iQure's clinical-stage asset iQ-007.
More news about: iQure Pharma Inc.
Sep 25, 2025, 07:37 ET Precision Medicine Protocol Shows Dual Benefits: Improved Cognition and Reduced Depression
have demonstrated that ReCODE can improve cognition in patients with early Alzheimer's and mild cognitive impairment. About CNS Vital Signs CNS Vital Signs is a leading provider of computerized neurocognitive assessments, offering clinicians efficient
More news about: Apollo Health
Sep 25, 2025, 07:00 ET Corero Network Security Enters Singapore Market Through Partnership with ONESECURE Asia
Corero Network Security (AIM: CNS) (OTCQX: DDOSF), a recognized leader in DDoS protection and champion of adaptive, real-time service availability, announced its strategic partnership
More news about: Corero Network Security
Sep 25, 2025, 06:30 ET AL-S Pharma Appoints Internationally Recognized Neurologist and Clinical Trial Expert Prof. Dr. Angela Genge as Chief Medical Officer
NeurimmuneNeurimmune is a biopharmaceutical company translating human immune memory into antibody therapeutics. Neurimmune develops drug candidates for CNS and related protein aggregation diseases including Alzheimer's disease, amyotrophic lateral sclerosis and ATTR cardiomyopathy. With its Reverse Translational
More news about: AL-S Pharma AG
Sep 25, 2025, 06:30 ET Immunic Presented Key Vidofludimus Calcium Data at the 41st Congress of ECTRIMS, Highlighting Its Potential in Multiple Sclerosis
central nervous system (CNS), including decreased number of pathogenic T helper cells producing interleukin-17A (IL-17A), granulocyte-macrophage colony-stimulating factor (GM-CSF), and interferon gamma (IFNγ). Prophylactic dosing also increased expression of Nurr1 target genes in the CNS, elevated plasma brain-derived
More news about: Immunic, Inc.
Sep 24, 2025, 19:00 ET Corero Network Security Masuk Pasar Singapura Melalui Kemitraan Dengan ONESECURE Asia
Corero Network Security (AIM: CNS) (OTCQX: DDOSF) adalah perusahaan terdepan yang diakui di bidang perlindungan DDoS dan yang terbaik dalam hal ketersediaan layanan adaptif di waktu nyata.
More news about: Corero Network Security
Sep 24, 2025, 10:52 ET Cognision and SOMNOmedics Forge Strategic Partnership to Advance Sleep Biomarkers in Pharmaceutical Clinical Trials
gold-standard electroencephalography (EEG) and event-related potential (ERP) biomarkers. "Sleep endpoints are becoming increasingly important in CNS drug development, from neurodegeneration and neuropsychiatric disorders to pain and emerging psychedelic therapies," said Dr. Igor
More news about: Cognision
Sep 24, 2025, 10:00 ET FYR Closes $8 Million Financing to Advance Blood-Based Biomarkers Across Oncology and Neuroscience
Two Bear Capital. "Their platform is scaling across solid tumors and also unlocks CNS applications where clean, noninvasive signals are notoriously hard to capture. We're excited to support the natural expansion of their platform into
More news about: FYR Diagnostics
Sep 24, 2025, 07:00 ET Corero Network Security Expands Partnership with Netceed to Strengthen UK Network Resilience
Corero Network Security (AIM: CNS) (OTCQX: DDOSF), a recognized leader in DDoS protection and champion of adaptive, real-time service availability, announced the expansion of its strategic
More news about: Corero Network Security
Sep 24, 2025, 02:45 ET New Novartis data further support benefits of Kesimpta® in relapsing MS following switch from oral disease modifying therapies
Beach, FL, US.Smith P, Huck C, Wegert V, et al. Low-dose, subcutaneous anti-CD20 therapy effectively depletes B-cells and ameliorates CNS autoimmunity. Poster presentation at: the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) Annual Meeting 2016; September
More news about: Novartis Pharmaceuticals Corporation
Sep 24, 2025, 02:00 ET Corero Network Security Expands Partnership with Netceed to Strengthen UK Network Resilience
Corero Network Security (AIM: CNS) (OTCQX: DDOSF), a recognized leader in DDoS protection and champion of adaptive, real-time service availability, announced the expansion of its strategic
More news about: Corero Network Security
Sep 23, 2025, 18:44 ET Cohen & Steers Closed-End Funds Declare Distributions for October, November and December 2025
https://www.cohenandsteers.com/Symbol: (NYSE: CNS)
More news about: Cohen & Steers, Inc.
Sep 23, 2025, 11:30 ET Inna Topiler, Leading Hashimoto's & Thyroid Expert, Launches ThyroLove: A Revolutionary Thyroid Supplement
NEW YORK, Sept. 23, 2025 /PRNewswire/ -- Inna Topiler, MS, CNS, founder of Complete Nutrition and Wellness and host of Thyroid Mystery Solved today announced the launch of ThyroLove, a breakthrough thyroid and immune
More news about: Complete Nutrition and Wellness
Sep 23, 2025, 07:00 ET Corero Network Security and Atlantic Data Security Form Strategic Business Resiliency Partnership
Corero Network Security (AIM: CNS) (OTCQX: DDOSF), a recognized leader in DDoS protection and champion of adaptive, real-time service availability, announced a new strategic partnership
More news about: Corero Network Security
Sep 22, 2025, 10:51 ET Neuraxpharm participates in ECTRIMS, reinforcing its commitment to multiple sclerosis
innovative solutions in the CNS field, some of which are based on advanced technologies resulting from strategic alliances. Neuraxpharm remains focused on innovation and investment in new solutions with the goal of improving the quality of life for people with CNS disorders. The company is committed
More news about: Neuraxpharm
Sep 22, 2025, 08:05 ET European Commission Approves Servier's VORANIGO® (vorasidenib) as the First Targeted Therapy for Grade 2 IDH-Mutant Glioma in the EU
into only three categories: Astrocytoma, IDH-mutant (CNS WHO grades 2-4) Oligodendroglioma, IDH-mutant and1p19q-codeleted (CNS WHO grades 2-3) Glioblastoma, IDH-wildtype (CNS WHO grade 4) VORANIGO IMPORTANT SAFETY INFORMATION FOR U.S. PATIENTS
More news about: Servier Pharmaceuticals